Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JK-1201I
- Development stage
- Phase 3
- Lead developer
- JenKem Technology
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
JK-1201I is a long-acting polymer-drug conjugate developed by JenKem Technology, consisting of the topoisomerase I inhibitor irinotecan conjugated to a polyethylene glycol (PEG) carrier. This PEGylation is designed to extend the half-life of the active metabolite SN-38, providing sustained therapeutic levels and potentially improving tumor penetration compared to conventional irinotecan. JK-1201I is primarily being evaluated for the treatment of glioblastoma multiforme (GBM), where it is administered intravenously in combination with adjuvant temozolomide following surgery and radio-chemotherapy. In addition to GBM, the drug is being investigated for other oncology indications, including small cell lung cancer, colorectal cancer, and triple-negative breast cancer with brain metastases, with some indications reaching Phase 3 development.
- Other names
- etirinotecan pegolPEG-Irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on JK-1201I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JK-1201I.